Are lomustine capsules suitable for pregnant and breastfeeding women?

Lomustine capsules (Lomustine), as a chemotherapy drug, are usually used to treat various malignant tumors, such as brain tumors, lymphoma, etc. However, due to its toxic effects on cells, the use of lomustine in pregnant and lactating women carries certain risks, and its use in pregnancy and lactation is generally not recommended unless absolutely necessary and after adequate risk assessment.

1. Use in pregnant women: The use of lomustine in pregnant women carries significant risks. According to the animal experimental data and clinical experience of the drug, lomustine has certain teratogenicity and embryotoxicity, which may lead to abnormal fetal development or other adverse consequences. The alkylation effect of the drug may interfere with fetal cell division and growth, increasing the risk of fetal developmental defects. Due to the lack of adequate clinical trial data, lomustine should be avoided during pregnancy unless other treatment options are available and the potential benefits of treatment outweigh the risks. In this case, treatment with lomustine should be strictly evaluated and decided by a physician.

2. Use during lactation: Whether lomustine will be passed to the baby through breast milk, there are currently no clear clinical research results. However, given the toxic properties of lomustine, especially its cytostatic effects, the use of lomustine in lactating women is not advisable. Medications may pass through breast milk and cause hematology, immune system, or other health problems in the baby. To avoid potential harm to the baby, breastfeeding women should suspend breastfeeding when treated with lomustine until the drug is completely metabolized and eliminated from the body.

In summary, lomustine capsules need to be used with special caution in pregnant and lactating women. Pregnant women should not use this drug except under strict guidance from their doctor and after a detailed risk assessment. During breastfeeding, use of lomustine may pose risks to the health of the infant and is not recommended. During the treatment process, if the patient is pregnant or lactating, she should fully communicate with her doctor to seek suitable alternative treatment options.